Edaravone Patent Expiration
Edaravone is Used for the treatment of amyotrophic lateral sclerosis (ALS). It was first introduced by Shionogi Inc
Edaravone Patents
Given below is the list of patents protecting Edaravone, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Radicava Ors | US12194025 | Pharmaceutical composition for oral administration of edaravone and method of administering same | Nov 12, 2041 | Shionogi |
| Radicava Ors | US12310946 | Pharmaceutical composition for oral administration of edaravone and method of administering same | Nov 12, 2041 | Shionogi |
| Radicava Ors | US12478611 | Pharmaceutical Composition For Oral Administration Of Edaravone And Method Of Administering Same | Nov 12, 2041 | Shionogi |
| Radicava Ors | US12527769 | Pharmaceutical Composition For Oral Administration Of Edaravone And Method Of Administering Same | Nov 12, 2041 | Shionogi |
| Radicava Ors | US12569469 | Pharmaceutical Composition For Oral Administration Of Edaravone And Method Of Administering Same | Nov 12, 2041 | Shionogi |
| Radicava Ors | US10987341 | Edaravone suspension for oral administration | Nov 01, 2039 | Shionogi |
| Radicava Ors | US11241416 | Edaravone suspension for oral administration | Nov 01, 2039 | Shionogi |
| Radicava Ors | US11478450 | Edaravone suspension for oral administration | Nov 01, 2039 | Shionogi |
| Radicava Ors | US11826352 | Edaravone suspension for oral administration | Nov 01, 2039 | Shionogi |
| Radicava Ors | US11957660 | Edaravone suspension for oral administration | Nov 01, 2039 | Shionogi |
| Radicava Ors | US12285409 | Edaravone suspension for oral administration | Nov 01, 2039 | Shionogi |
| Radicava Ors | US12599586 | Edaravone Suspension For Oral Administration | Nov 01, 2039 | Shionogi |
| Radicava | US6933310 | Therapeutic agent for amyotrophic lateral sclerosis (ALS) |
Nov 13, 2020
(Expired) | Shionogi |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Edaravone's patents.
Latest Legal Activities on Edaravone's Patents
Given below is the list recent legal activities going on the following patents of Edaravone.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 23 Jul, 2025 | US11241416 |
| Patent eCofC Notification | 20 May, 2025 | US11826352 |
| Email Notification | 20 May, 2025 | US11826352 |
| Mail Patent eCofC Notification | 20 May, 2025 | US11826352 |
| Recordation of Patent eCertificate of Correction | 20 May, 2025 | US11826352 |
| Post Issue Communication - Certificate of Correction | 30 Apr, 2025 | US11826352 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 09 Oct, 2024 | US10987341 |
| Mail Patent eGrant Notification | 16 Apr, 2024 | US11957660 |
| Email Notification Critical
| 16 Apr, 2024 | US11957660 |
| Patent eGrant Notification | 16 Apr, 2024 | US11957660 |
Edaravone's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Edaravone:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
